All News

Found 2,622 articles

• Alcanza Partners with Climb to Enhance the Clinical Trial Patient Experience

  5/31/2023

  To enhance the patient experience throughout a clinical trial journey, Alcanza Clinical Research, a mission-driven investigator site network, announces a partnership with Climb, a provider of digital clinical trial solutions.

• 

  The Top Biotech Companies in Boston Hiring Now

  5/30/2023

  Check out these hot Boston-based biotech companies hiring now.

• Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13

  5/30/2023

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 44th Annual Global Healthcare Conference.

• ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth

  5/24/2023

  ElevateBio, LLC announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by Matrix Capital Management, and joined by a leading group of new and existing investors.

• Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments

  5/23/2023

  Company also adds Dr. Parameswaran Hari as Chief Development Officer and appoints Dr. Matthew Norkunas to Board of Directors.

• 

  ReCode–a New Contestant in the mRNA Race  

  5/22/2023

  ReCode plans to use its SORT LNP genetic medicines delivery technology to treat CF and PCD patients who don’t respond to current treatments.

• Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

  5/22/2023

  Kymera Therapeutics, Inc. today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.

• Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer

  5/17/2023

  Indapta Therapeutics, Inc. today announced that the company has reached agreement with the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application to commence its first-in-human phase 1 trial in patients with multiple myeloma and lymphoma anticipated to begin in the second half of 2023.

• Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncogene Amplified Cancer

  5/16/2023

  Boundless Bio today announced the closing of a $100 million Series C financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors, Sectoral Asset Management and Piper Heartland Healthcare Capital.

• Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

  5/11/2023

  Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatment of male androgenetic alopecia ("AGA") in the US has been completed successfully.

• Forge Biologics Announces Eight Presentations at the Upcoming 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)

  5/11/2023

  Forge Biologics will be delivered during the upcoming 26th Annual Meeting of the American Society of Gene and Cell Therapy.

• MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

  5/10/2023

  MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced financial results for the first quarter ended March 31, 2023, and updated 2023 revenue guidance.

• Entrada Therapeutics Reports First Quarter 2023 Financial Results

  5/10/2023

  Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent business updates.

• Laronde Announces New Leadership - May 08, 2023

  5/8/2023

  Laronde, the company pioneering Endless RNA™ – a novel, engineered form of RNA that can be programmed to express proteins inside the body for breakthrough treatments – announced that Pablo J. Cagnoni, M.D., will step down from his role as Chief Executive Officer effective May 26, 2023, to become President and Head of Research & Development of Incyte.

• Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

  5/8/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the first quarter 2023.

• Mammoth Biosciences to Present at the 2023 Annual Meeting of the American Society of Gene and Cell Therapy

  5/8/2023

  Mammoth Biosciences today announced Janice Chen, Ph.D., chief technology officer and co-founder of Mammoth, will present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, CA, May 16 - 20, 2023.

• CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

  5/8/2023

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2023.

• Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

  5/4/2023

  Kymera Therapeutics, Inc. today reported business highlights and financial results for the first quarter ended March 31, 2023.

• Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older

  5/3/2023

  Vertex Announces U.S. FDA Approval for KALYDECO ® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older.

• Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results

  5/3/2023

  Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced the appointment of Ron Renaud as president and chief executive officer, and member of the company’s board of directors, effective June 12, 2023.